Reviews: Effects of Transdermal Rivastigmine on ADAS-Cog Items in Mild-to-Moderate Alzheimer’s Disease
| Autor: | George T. Grossberg, Frederick A. Schmitt, Sibel Tekin, Xiangyi Meng, Jason T. Olin |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
Transdermal patch Phenylcarbamates Rivastigmine Disease Administration Cutaneous Individual item Placebo Severity of Illness Index Cognition Alzheimer Disease Internal medicine medicine Humans Aged Transdermal General Neuroscience Clinical trial Psychiatry and Mental health Clinical Psychology Neuroprotective Agents Adas cog Controlled Clinical Trials as Topic Geriatrics and Gerontology Psychology Clinical psychology medicine.drug |
| Zdroj: | American Journal of Alzheimer's Disease & Other Dementiasr. 25:627-633 |
| ISSN: | 1938-2731 1533-3175 |
| DOI: | 10.1177/1533317510385808 |
| Popis: | Alzheimer’s disease (AD) patients treated with rivastigmine transdermal patch have shown statistically significant differences versus placebo on the AD Assessment scale-cognitive subscale (ADAS-cog). In this retrospective analysis of a double-blind, placebo- and active-controlled, 24-week clinical trial, the specific effects of rivastigmine patch on individual ADAS-cog items and cognitive domains (memory, language, and praxis) were explored. The mean baseline to week 24 changes were calculated for each ADAS-cog item and domain in this exploratory, hypothesis-generating analysis. Patients on 9.5 mg/24 h rivastigmine patch, 17.4 mg/24 h rivastigmine patch, and 3 to 12 mg/d rivastigmine capsules showed improvements over placebo on the memory and praxis ADAS-cog subscales. The rivastigmine patch groups also showed improvements on the language subscale. Significant differences versus placebo were seen on several individual item scores in the rivastigmine-treated groups. Rivastigmine patch was associated with improvements on the memory, praxis, and language domains of cognition in patients with mild-to-moderate AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|